Reduction of fusion transcript ratio in 73 CBF AML patients. Thirty-three (45.2%) in the HDAC-123 arm and 40 (54.8%) in the HDAC-135 arm, at CR1/CRi1, median ratio at diagnosis (Diag), and at the MRD1, MRD2, MRD3, and MRD4 time points, for the HDAC-123 arm (red bars) and HDAC-135 arm (blue bars), in bone marrow (A) and in blood (B). Outcomes among patients with newly diagnosed CBF-AML in CR1/CRi1: overall survival by treatment arm (n = 73; P = .54) (C) and relapse-free survival by treatment arm (n = 73; P = .52) (D).